What is Roth Capital’s Forecast for CELZ FY2028 Earnings?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) – Equities researchers at Roth Capital cut their FY2028 earnings per share estimates for Creative Medical Technology in a report issued on Wednesday, February 12th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings of $6.02 per share for the year, down from their prior estimate of $6.34. The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.19) per share. Roth Capital also issued estimates for Creative Medical Technology’s FY2029 earnings at $7.83 EPS.

Creative Medical Technology Trading Up 3.3 %

NASDAQ:CELZ opened at $4.74 on Friday. The stock’s 50 day simple moving average is $2.66 and its 200-day simple moving average is $3.07. Creative Medical Technology has a 12-month low of $1.96 and a 12-month high of $10.28. The firm has a market cap of $8.29 million, a P/E ratio of -1.25 and a beta of 1.85.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Creative Medical Technology stock. Geode Capital Management LLC bought a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned approximately 0.59% of Creative Medical Technology as of its most recent filing with the Securities and Exchange Commission (SEC). 1.42% of the stock is owned by institutional investors and hedge funds.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.